{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:19Z","timestamp":1784115499076,"version":"3.55.0"},"reference-count":86,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-bisphosphonate (BP) synthetized in Italy in 1986. Bisphosphonates are molecules with a P-C-P bond in their structure that allows strong and selectively binding to hydroxyapatite (HAP) as well as osteoclasts inhibition through different mechanisms of action. Neridronate was initially used to treat Paget disease of the bone, demonstrating effectiveness in reducing bone turnover markers as well as pain. The interesting molecular properties of neridronate foster its wide use in several other conditions, such as osteogenesis imperfecta, and osteoporosis. Thanks to the unique safety and efficacy profile, neridronate has been used in secondary osteoporosis due to genetic, rheumatic, and oncological diseases, including in pediatric patients. In the last decade, this drug has also been studied in chronic musculoskeletal pain conditions, such as algodystrophy, demonstrating effectiveness in improving extraskeletal outcomes. This review highlights historical and clinical insights about the use of neridronate for metabolic bone disorders and musculoskeletal pain conditions.<\/jats:p>","DOI":"10.3390\/ijms23136921","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:31:06Z","timestamp":1655933466000},"page":"6921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-925X","authenticated-orcid":false,"given":"Giovanni","family":"Iolascon","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties and Dentistry, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-2891","authenticated-orcid":false,"given":"Antimo","family":"Moretti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties and Dentistry, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1517\/17425250903029190","article-title":"Neridronic acid for the treatment of bone metabolic diseases","volume":"5","author":"Gatti","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/cr0503613","article-title":"The Oceanic Phosphorus Cycle","volume":"107","author":"Paytan","year":"2007","journal-title":"Chem. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fendo.2019.00180","article-title":"Roles of Phosphate in Skeleton","volume":"10","author":"Michigami","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00223-019-00636-8","article-title":"Phosphate as a Signaling Molecule","volume":"108","author":"Kritmetapak","year":"2021","journal-title":"Calcif. Tissue Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00223-020-00686-3","article-title":"Phosphate Metabolism in Health and Disease","volume":"108","author":"Peacock","year":"2021","journal-title":"Calcif. Tissue Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16987","DOI":"10.1074\/jbc.X112.363200","article-title":"How Enzymes Handle the Energy Derived from the Cleavage of High-energy Phosphate Compounds","volume":"287","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1021\/jp0556862","article-title":"Energy Transfer from Adenosine Triphosphate","volume":"110","author":"Ross","year":"2006","journal-title":"J. Phys. Chem. B"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/hdi.12010","article-title":"Phosphorus, phosphorous, and phosphate","volume":"17","author":"Iheagwara","year":"2013","journal-title":"Hemodial. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/j.1551-8833.1957.tb15525.x","article-title":"Evaluation of the Use of Polyphosphates in the Water Industry","volume":"49","author":"Larson","year":"1957","journal-title":"J. Am. Water Work. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/bj1020053","article-title":"Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations","volume":"102","author":"Moss","year":"1967","journal-title":"Biochem. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0003-9861(68)90335-4","article-title":"Lysosomal acid pyrophosphatase and acid phosphatase","volume":"124","author":"Brightwell","year":"1968","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/1529-0131(197605\/06)19:3+<465::AID-ART1780190722>3.0.CO;2-#","article-title":"Metabolism of inorganic pyrophosphate (PPi)","volume":"19","author":"Russell","year":"1976","journal-title":"Arthritis Rheum."},{"key":"ref_15","first-page":"804","article-title":"Pharmacist Theodor Salzer (1833\u20131900) and the discovery of bisphosphonates","volume":"66","author":"Petroianu","year":"2011","journal-title":"Pharmazie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0221-8747(81)90044-8","article-title":"Diphosphonates: History and mechanisms of action","volume":"3","author":"Fleisch","year":"1981","journal-title":"Metab. Bone Dis. Relat. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","article-title":"The pharmacology of bisphosphonates and new insights into their mechanisms of action","volume":"14","author":"Russell","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.biochem.78.091707.100215","article-title":"Biosynthesis of Phosphonic and Phosphinic Acid Natural Products","volume":"78","author":"Metcalf","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0304-4165(71)90139-5","article-title":"2-Aminoethylphosphonic acid: Distribution in human tissues","volume":"244","author":"Alhadeff","year":"1971","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.144.3622.1133","article-title":"2-Aminoethylphosphonic Acid in Insoluble Protein of the Sea Anemone Metridium dianthus","volume":"144","author":"Quin","year":"1964","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2113386119","DOI":"10.1073\/pnas.2113386119","article-title":"Phosphonate production by marine microbes: Exploring new sources and potential function","volume":"119","author":"Acker","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","unstructured":"Churchill, D.G., Sikiri\u0107, M.D., \u010colovi\u0107, B., and Milhofer, H.F. (2019). Phosphonates: Their Natural Occurrence and Physiological Role. Contemporary Topics about Phosphorus in Biology and Materials, IntechOpen. Available online: https:\/\/www.intechopen.com\/chapters\/67886."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3181\/00379727-122-31123","article-title":"Effect of Pyrophosphate on Dissolution of Hydroxyapatite and Its Possible Importance in Calcium Homeostasis","volume":"122","author":"Fleisch","year":"1966","journal-title":"Proc. Soc. Exp. Bio."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02546591","article-title":"The effect of phosphonates on dental enamel in vitro and calculus formation in vivo","volume":"11","author":"Francis","year":"1973","journal-title":"Calcif. Tissue Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02058658","article-title":"The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates","volume":"3","author":"Francis","year":"1969","journal-title":"Calcif. Tissue Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/223211a0","article-title":"Prevention by a diphosphonate of immobilisation \u2018osteoporosis\u2019 in rats","volume":"223","author":"Fleisch","year":"1969","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","article-title":"Diphosphonates in the treatment of myositis ossificans","volume":"294","author":"Bassett","year":"1969","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","article-title":"Diphosphonates and Paget\u2019s disease of bone","volume":"1","author":"Smith","year":"1971","journal-title":"Lancet"},{"key":"ref_31","first-page":"894","article-title":"Diphosphonates in Paget\u2019s disease","volume":"1","author":"Russell","year":"1974","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.1780231015","article-title":"Use of etidronate (EHDP) in Paget\u2019s disease of bone","volume":"23","author":"Johnston","year":"1980","journal-title":"Arthritis. Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3109\/17453677408989703","article-title":"Effect of a Diphosphonate on Para-Articular Ossification after total Hip Replacement","volume":"45","author":"Bijvoet","year":"1974","journal-title":"Acta Orthop. Scand."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.1984.00350180234034","article-title":"Immobilization hypercalcemia in acute spinal cord injury treated with etidronate","volume":"144","author":"Merli","year":"1984","journal-title":"Arch. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0003-9993(97)90032-0","article-title":"Cyclical etidronate: Its effect on bone density in patients with acute spinal cord injury","volume":"78","author":"Pearson","year":"1997","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archinte.1985.00360030089018","article-title":"Intravenous etidronate in the management of malignant hypercalcemia","volume":"145","author":"Ryzen","year":"1985","journal-title":"Arch. Intern. Med."},{"key":"ref_37","first-page":"69","article-title":"Optimization of the ratio of stannous tin: Ethane-1-hydroxy-1, 1-diphosphonate for bone scanning with 99mTc-pertechnetate","volume":"15","author":"Tofe","year":"1974","journal-title":"J. Nucl. Med."},{"key":"ref_38","first-page":"270","article-title":"The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease","volume":"19","author":"Fogelman","year":"1978","journal-title":"J. Nucl. Med."},{"key":"ref_39","first-page":"S443","article-title":"Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency together drive in vivo efficacy","volume":"22","author":"Lundy","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00223-002-2017-2","article-title":"The Role of Prenylated Small GTP-Binding Proteins in the Regulation of Osteoclast Function","volume":"72","author":"Coxon","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the Actin Cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(08)61608-3","article-title":"Role of Rab GTPases in Membrane Traffic","volume":"176","author":"Olkkonen","year":"1997","journal-title":"Int. Rev. Cytol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bst0200479","article-title":"Geranylgeranylated proteins","volume":"20","author":"Glomset","year":"1992","journal-title":"Biochem. Soc. Trans."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"154264","DOI":"10.1016\/j.metabol.2020.154264","article-title":"Extra-skeletal effects of bisphosphonates","volume":"110","author":"Panagiotakou","year":"2020","journal-title":"Metabolism"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00198-011-1891-8","article-title":"Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications","volume":"23","author":"Body","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Santos, J.C.B., De Melo, J.A., Maheshwari, S., de Medeiros, W.M.T.Q., de Freitas Oliveira, J.W., Moreno, C., Amzel, L.M., Gabelli, S.B., and Silva, M.S. (2020). Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs. Molecules, 25.","DOI":"10.3390\/molecules25112602"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100317","DOI":"10.1016\/j.jbo.2020.100317","article-title":"Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions","volume":"25","author":"George","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20580","DOI":"10.1038\/srep20580","article-title":"The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells","volume":"6","author":"Sharma","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","article-title":"Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro","volume":"17","author":"Walter","year":"2011","journal-title":"Oral Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Adjei-Sowah, E., Peng, Y., Weeks, J., Jonason, J., Bentley, K.D.M., Masters, E., Morita, Y., Muthukrishnan, G., Cherian, P., and Hu, X. (2021). Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060732"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acsomega.7b01686","article-title":"Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial Applications","volume":"3","author":"Tal","year":"2018","journal-title":"ACS Omega"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3389\/fmicb.2017.02329","article-title":"Conjugation Inhibitors and Their Potential Use to Prevent Dissemination of Antibiotic Resistance Genes in Bacteria","volume":"8","author":"Arechaga","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10529-011-0542-7","article-title":"Co-loading of bisphosphonates and antibiotics to a biomimetic hydroxyapatite coating","volume":"33","author":"Forsgren","year":"2011","journal-title":"Biotechnol. Lett."},{"key":"ref_56","unstructured":"PubChem (2022, May 01). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. PubChem Compound Summary for CID 71237. Neridronic Acid, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Neridronic-acid."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif. Tissue Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jbmr.5650020403","article-title":"Aminohexane diphosphonate in the treatment of paget\u2019s disease of bone","volume":"2","author":"Atkins","year":"1987","journal-title":"J. Bone Miner. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous Neridronate in Adults With Osteogenesis Imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous Neridronate in Children with Osteogenesis Imperfecta: A Randomized Controlled Study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bone.2017.07.004","article-title":"Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study","volume":"103","author":"Idolazzi","year":"2017","journal-title":"Bone"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","article-title":"Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study","volume":"100","author":"Viapiana","year":"2017","journal-title":"Calcif. Tissue Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF03345373","article-title":"Effects of neridronate treatment in elderly women with osteoporosis","volume":"28","author":"Cascella","year":"2005","journal-title":"J. Endocrinol. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-008-9179-5","article-title":"Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density","volume":"83","author":"Adami","year":"2008","journal-title":"Calcif. Tissue Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00223-011-9489-x","article-title":"Long-Term Effects of Neridronate and its Discontinuation in Patients with Primary Hyperparathyroidism","volume":"89","author":"Rossini","year":"2011","journal-title":"Calcif. Tissue Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF03324436","article-title":"Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: Effects on disease activity and bone resorption markers","volume":"14","author":"Mazzantini","year":"2002","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","article-title":"Bisphosphonates vs infliximab in ankylosing spondylitis treatment","volume":"53","author":"Viapiana","year":"2014","journal-title":"Rheumatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.1994.176","article-title":"Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)","volume":"69","author":"McCloskey","year":"1994","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/JBMR.040813","article-title":"Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer","volume":"19","author":"Morabito","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.eururo.2005.01.012","article-title":"Preventing Bone Loss During Androgen Deprivation Therapy for Prostate Cancer: Early Experience with Neridronate","volume":"47","author":"Magno","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_78","first-page":"81","article-title":"Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma","volume":"77","author":"Pittari","year":"2006","journal-title":"Acta Biomed."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.23736\/S0031-0808.21.04401-3","article-title":"Effect of neridronate in osteopenic patients after heart, liver or lung transplant: A multicenter, randomized, double-blind, placebo-controlled study","volume":"63","author":"Giannini","year":"2021","journal-title":"Panminerva Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Moretti, A., Liguori, S., Paoletta, M., Gimigliano, F., and Iolascon, G. (Adv Ther., 2022). Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study, Adv Ther., Epub ahead of print.","DOI":"10.1007\/s12325-022-02179-1"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","article-title":"Neridronate improves bone mineral density and reduces back pain in \u03b2-thalassaemia patients with osteoporosis: Results from a phase 2, randomized, parallel-arm, open-label study","volume":"158","author":"Forni","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/14656566.2019.1612367","article-title":"Pharmacotherapeutic options for complex regional pain syndrome","volume":"20","author":"Iolascon","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_83","first-page":"26","article-title":"Treatment of complex regional pain syndrome","volume":"12","author":"Resmini","year":"2015","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/kes312","article-title":"Treatment of complex regional pain syndrome type I with neridronate: A randomized, double-blind, placebo-controlled study","volume":"52","author":"Varenna","year":"2013","journal-title":"Rheumatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1759720X211014020","DOI":"10.1177\/1759720X211014020","article-title":"Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: A randomized, double-blind, placebo-controlled study","volume":"13","author":"Varenna","year":"2021","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/rheumatology\/kev123","article-title":"Intravenous neridronate in the treatment of acute painful knee osteoarthritis: A randomized controlled study","volume":"54","author":"Varenna","year":"2015","journal-title":"Rheumatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/6921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:35Z","timestamp":1760139455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/6921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":86,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23136921"],"URL":"https:\/\/doi.org\/10.3390\/ijms23136921","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}